It’s time for new molecular insights in bladder cancer

Global Solid Tumor Summit

On April 25 and 26, hear how advances in technology, such as dPCR and NGS are driving improvements in biomarker testing in solid tumors.

FGFR alterations in urothelial cancer

Fibroblast growth factor receptors (FGFRs) are membrane-bound receptor tyrosine kinases that initiate intracellular signaling pathways involved in proliferation, differentiation, migration and angiogenesis. Activating alterations within the FGFR genes have been found in a subset of urothelial cancer patients (2, 3), demonstrating the importance of this type of genetic defect as a driver of tumor development and progression.

Reliably detect actionable genetic alterations

The therascreen FGFR RGQ RT-PCR Kit version 2 is a unique molecular test to identify actionable genetic alterations in patients with urothelial cancer, who may be eligible for treatment with BALVERSA (erdafitinib), an FGFR inhibitor drug.

Find a lab offering the test.

Give your oncologists results they can trust

The therascreen FGFR RGQ RT-PCR Kit is the first FDA-approved companion diagnostic (CDx) test to detects two point mutations in exon 7 [p.R248C (c.742C>T) and p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) in the FGFR3 gene in RNA samples derived from clinical formalin-fixed paraffin-embedded (FFPE) UC tissue.

Enabling precision healthcare for your patients

Our therascreen kits for solid tumor diagnostics allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Get the latest insights from oncology experts

Catch up with our solid tumor webinars wherever you are, at a time that works for you.